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Abstract
The increased incidence, high rates of mortality and few effective means of treatment of malignant melanoma, stimulate the
search for new anti-tumor agents and therapeutic targets to control this deadly metastatic disease. In the present work the
antitumor effect of arazyme, a natural bacterial-derived metalloprotease secreted by Serratia proteomaculans, was
investigated. Arazyme significantly reduced the number of pulmonary metastatic nodules after intravenous inoculation of
B16F10 melanoma cells in syngeneic mice. In vitro, the enzyme showed a dose-dependent cytostatic effect in human and
murine tumor cells, and this effect was associated to the proteolytic activity of arazyme, reducing the CD44 expression at
the cell surface, and also reducing in vitro adhesion and in vitro/in vivo invasion of these cells. Arazyme treatment or
immunization induced the production of protease-specific IgG that cross-reacted with melanoma MMP-8. In vitro, this
antibody was cytotoxic to tumor cells, an effect increased by complement. In vivo, arazyme-specific IgG inhibited melanoma
lung metastasis. We suggest that the antitumor activity of arazyme in a preclinical model may be due to a direct cytostatic
activity of the protease in combination with the elicited anti-protease antibody, which cross-reacts with MMP-8 produced
by tumor cells. Our results show that the bacterial metalloprotease arazyme is a promising novel antitumor
chemotherapeutic agent.
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Introduction
Melanoma is a fatal skin cancer, with increased incidence in
recent years [1,2]. Despite improvements in awareness and early
detection, the mortality in patients with melanoma is still quite
high [3]. A median survival of 8–18 months after diagnosis of
metastatic melanoma has been observed [4]. Until 2011, only
dacarbazine and high-dosage of interleukin-2 had been approved
for melanoma treatment by the Food and Drug Administration
(FDA), with durable responses in some patients with metastatic
disease [5,6]. Recently, the newly approved therapies, ipilimumab
(anti-CTLA-4 antibody) and vemurafenib (B-RAFV600E kinase
inhibitor), have shown a survival benefit in large randomized
clinical trials, but still with low frequency of objective results [7,8].
Chemotherapy used against metastatic melanoma often generates
a large number of adverse side effects, leading to interruption of
the treatment [9].
The discovery and introduction of new therapeutic agents and
strategies is thus actively encouraged in order to expand the few
treatment options for metastatic melanoma, and there has been a
long-standing interest in the identification of plant- and bacterial-
derived natural products for developing anticancer agents.
Exogenous proteinases administered in the form of a multien-
zyme mixture composed of trypsin, chymotrypsin and papain,
effectively inhibited tumor growth in experimental models [10].
Mice treated with bromelain (an extract containing a mixture of
proteolytic enzymes prepared from pineapples, Ananas comosus) and
fastuosain (a 25 kDa cysteine protease purified from the unripe
fruits of Bromelia fastuosa) were equally protective against tumor
development [11]. The antitumor activities of bacterial-derived
proteases are less recognized.
Inhibition of endogenous matrix metalloproteases (MMPs) in
vivo could be a target for cancer treatment. MMPs are linked to
invasion and metastasis of tumor cells mediating extracellular
matrix (ECM) disruption, and recently they have also been
implicated in tumor growth and angiogenesis [12]. However,
metalloprotease inhibitors (e.g. metal chelators) are not specific
and could affect normal enzymatic reactions. Recent evidence has
shown that inhibited secretion of MMPs reduced tumor cell
migration and angiogenesis [13,14]. Moreover, blockade of MMP-
14 by a monoclonal antibody in MMP-14-expressing ovarian
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tumor cells, inhibited aggressive metastatic tumor development in
a preclinical model [15].
Arazyme is a 51.5 kDa metalloprotease secreted by Serratia
proteamaculans, a symbiotic bacterium from Nephila clavata spider.
Large amounts of the enzyme can be obtained per liter of bacterial
culture (in order of grams), the enzymatic activity being
maintained under aggressive conditions [16,17]. A hepatoprotec-
tive effect of arazyme was shown in the model of acute liver injury
induced by CCl4, leading to overexpression of SMP30, inhibition
of TGF-b/Smad pathway and increased expression of antioxidant
proteins [18].
In the present work we show that arazyme has a potent
inhibitory effect on metastatic melanoma B16F10 preclinical
model in vivo. This effect was attributed to a direct action of
arazyme on tumor cells, in association with the induction of
protease-specific antibodies recognizing the melanoma MMP-8,
that may target this enzyme in the tumor cell environment, both
actions interfering with melanoma development.
Materials and Methods
Cell lines and culture conditions
The murine melanoma cell line B16F10-Nex2, syngeneic to
C57Bl/6 mice, was established at the Experimental Oncology
Unit, Paulista School of Medicine, Federal University of Sa˜o Paulo
(EPM-UNIFESP), as described elsewhere [19]. Human melanoma
cell line A2058 (CRL-11147, ATCC) and human breast carcino-
ma SKBR3 (HTB-30, ATCC) were donated by the Ludwig
Institute for Cancer Research, Sa˜o Paulo, Brazil. Human cervical
carcinoma (HeLa, CCL-2, ATCC) cell line was gifted by Dr.
Hugo P. Monteiro, EPM-UNIFESP. Cells were maintained in
culture flasks at 37uC in a humidified atmosphere with 5% CO2 in
RPMI 1640 medium (pH 7.2; Invitrogen, USA) supplemented
with 10 mM HEPES (N-2-hydroxyethylpiperazine-N-2-ethanesul-
phonic acid), 24 mM sodium bicarbonate, 10% fetal calf serum
(FCS, all from Invitrogen, NY, USA) and 40 mg/mL gentamicin
(Hipolabor Farmaceutica, MG, Brazil).
Animals
Inbred male C57Bl/6 mice, 6–8 weeks old, and male albino
rabbits, 6 weeks old, were purchased from Center for Develop-
ment of Experimental Models (CEDEME), at UNIFESP. All
animal experiments were approved by the Animal Experimenta-
tion Ethics Committee, UNIFESP, under the protocol number
0288/12.
Arazyme purification and determination of proteolytic
activity
The supernatant of S. proteamaculans culture medium, obtained
from Insect Biotech, Korea, was subjected to membrane filtration
and concentrated 3–10 times through 10 kDa cut-off membranes.
Protease purification was performed by ion exchange chromatog-
raphy in a Resource Q column (1 mL, GE Healthcare, Piscat-
away, NJ, USA) equilibrated with 20 mM Tris-HCl, pH 8.0 and
eluted with a gradient of NaCl (0 to 0.5 M), using a Akta Purifier
system (GE Healthcare, Uppsala, Sweden). The profile of protein
elution was monitored by UV absorbance (280 nm). Fractions of
1 mL were collected at a flow rate of 1 mL/min and protease
activity was measured using the synthetic fluorescence resonance
energy transfer (FRET) peptide Abz-KLRFSKQ-EDDnp, as
described in [16]. Briefly, the test was performed in 50 mM
Tris-HCl, pH 8.0 at 37uC, and fluorescence was continuously
monitored at lex = 320 nm and lem = 420 nm (1.0 mL final
volume) in a Hitachi F-2000 spectrofluorometer (Tokyo, Japan).
The inactivated enzyme was obtained by incubation of the
purified arazyme at 50uC for 30 min, or by incubation with 2 mM
of ortho-phenantroline for 5 min. Both treatments inhibited 100%
of protease activity, as described previously [16].
Cell viability assay
A2058, HeLa and B16F10-Nex2 tumor cells were plated into
96-well plates (103 cells/100 mL of medium/well) and treated with
increasing concentrations of active or inactive arazyme (in 100 mL
of medium) for 24 or 48 hours. Total cells, in the supernatant and
adherent cells collected after 0.05% EDTA treatment, were
counted in presence of Trypan blue. The percentage of viable and
nonviable cells was calculated compared to untreated cells,
considered as 100%.
Adhesion assay
For the adhesion assay, A2058 and B16F10-Nex2 cells (56104
cells/well) were treated with arazyme (10 mg/mL) for 1 hour,
added to 96-well plates and incubated for 3 hours at 37uC. Plates
were gently washed twice with PBS to remove unattached cells
and the attached cells were fixed with methanol on ice for 5 min.
Fixed cells were stained with toluidine blue 1% in sodium
tetraborate 1% for 5 min and washed with PBS. Dye was
solubilized in SDS 1% for 20 min at 37uC and the resulting
colored solution was quantified at 540 nm using a scanning
multiwell spectrophotometer. Cells incubated without arazyme
were used as control and represent one hundred percent of
adhesion.
Matrigel Invasion Assay
Arazyme effect on B16F10-Nex2 cell invasion was determined
as described elsewhere [11]http://www.ncbi.nlm.nih.gov/
pubmed/17898868. Briefly, 56 mL (50 mg) of 1:3 (vol:vol)
serum-free RPMI-diluted cold Matrigel (Basement Membrane
Matrix, BD Biosciences, NJ, USA) was added to the upper
transwell chambers (8-mm pore size, Corning Costar Co., MA,
USA) and incubated for 30 min at 37uC for gel formation. The
lower chambers were filled with FCS-containing RPMI medium.
Tumor cells (26105/mL) were treated with arazyme (5 or 10 mg/
mL) in serum-free RPMI medium for 1 hour at 37uC and 5%
CO2, washed, resuspended in 0.2 mL of serum-free RPMI, added
to the upper transwell compartment and incubated for 5 hours at
37uC, 5% CO2. After removal of non-invading cells with a cotton
swab from the top of the membrane, cells underneath the
membrane filter were fixed in paraformaldehyde (3.7%) for 15
min, stained with 0.1% toluidine blue solution for 2 min at 37uC
and after washing with tap water, the filters were incubated with
200 mL of 1% SDS solution for 1 hour at 37uC. This solution was
transferred to a 96-well ELISA plate, and absorbance was
measured at 600 nm. The percentage of invasion was calculated
compared to the untreated control, taken as 100%.
Flow Cytometry analysis of CD44 on tumor cells
B16F10-Nex2 or A2058 tumor cells (106 cells/well in 24-well
plates) were incubated with arazyme at different concentrations,
treated or not with ortho-phenantroline for inactivation, in serum-
free RPMI medium for 1 hour at 37uC. Cells were collected,
transferred to a 1.5-mL microtube and after enzyme removal by
PBS washing cells were resuspended in PBS containing 10% BSA
and incubated for 10 min on ice. After washing, 1 mg of FITC-
conjugated antibody against mouse or human CD44 (BD
Biosciences, San Jose, CA) was diluted in 50 mL of PBS containing
1% BSA and added to the cells. After incubation on ice for 1 hour
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protected from light cells were washed and resuspended in 2%
cold paraformaldehyde (wt/vol). Fluorescence was measured on a
FACScan flow cytometer (BD Biosciences) and data were analyzed
by CellQuest software (Becton Dickinson, San Jose, CA).
CD44 mRNA quantification by real-time PCR
CD44 mRNA expression from 106 B16F10-Nex2 and A2058
cells treated or not with arazyme (10 mg/mL) for 1 hour was
analysed by real-time PCR. Total RNA extraction was performed
using TRIzol reagent (Gibco-BRL, NY, USA) composed of a
monophasic solution of phenol and guanidine isothiocyanate,
according to the method described by Chomczynski and Sacchi
[20]. Extracted RNA was quantified using a Nanodrop 2000
Spectrophotometer (Thermo Scientific, MA, USA) and read at
260 nm and 280 nm. All samples with A260/280 greater than 1.8
were considered adequate for the experiments. The synthesis of
cDNA was performed using High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, NY, USA) following
manufacturer’s instructions. Specific mRNA expression was
assessed by SYBR Green real-time PCR using 100 ng of cDNA
total, Universal SYBR Green Master Mix (Applied Biosystems),
and the following pairs of primers in separate reactions: murine
CD44 (forward 59 CATCGAGAAGAGCACCCCAG 39, reverse
59 TGAGTGCACAGTTGAGGCAA 39), human CD44 (forward
59 TCCCAGACGAAGACAGTCCCTGGAT 39, reverse 59
CACTGGGGTGGAATGTGTCTTGGTC 39), human GAPDH
(forward 59 TGCACCACCAACTGCTTAGC 39, reverse 59
GGCATGGACTGTGGTCATGAG 39) and murine HPRT
(forward 59GCTGGTGAAAAGGACCTCT 39, reverse 59CA-
CAGGACTAGAACACCTGC 39). CD44, GAPDH and HPRT
mRNA expressions were obtained from the cycle threshold (Ct)
associated with the exponential growth of the PCR products.
Quantitative values for CD44 mRNA expression were obtained by
the parameter 2–DDCt, in which DCt represents the subtraction of
the GAPDH or the HPRT Ct values from the CD44 Ct values.
Production, purification and detection by ELISA of
polyclonal monospecific arazyme-specific antibodies
C57Bl/6 mice were treated i.p. with arazyme (3 mg/kg/dose)
every other day for 21 days. Serum was collected 3 days after the
last injection and arazyme binding specificity of serum antibodies
was evaluated by ELISA. Briefly, high-binding ELISA plates
(Nunc, Thermo Fisher Scientific, NY, USA) were coated with 1 mg
of arazyme. After blocking, plates were incubated with serial
dilutions of individual sera, 1:100 to 1:800. Reaction was revealed
with Horseradish Peroxidase (HRP)-conjugated anti-mouse IgG
secondary antibodies and DAB (3,39-Diaminobenzidine tetrahy-
drochloride), and read in a Multiskan ELISA reader at 492 nm.
Additionally, mouse IgG fraction was affinity-purified from pooled
sera using a Protein G column (Hi-Trap Protein G affinity column,
Amersham Biosciences, Piscataway, NJ).
Male albino rabbits were immunized subcutaneously with 6
doses of 100 mg of arazyme emulsified in alum as adjuvant (v/v,
Sigma-Aldrich, MO, USA) every 15 days. Before each immuni-
zation serum samples were collected to evaluate the production of
arazyme-specific immunoglobulins by ELISA. The serum was
inactivated by incubation at 56uC for 30 min, and stored at 2
80uC in aliquots of 500 mL until purification of antibodies by
Protein G affinity chromatography.
Western blot
B16F10-Nex2 cell lysate (36107 cells) was prepared by several
rounds of freezing in liquid nitrogen and rapid thawing at 37uC.
For immunoblot analysis, 40 mg of total tumor cell protein, 100 mg
of recombinant murine matrix metalloprotease 1, 2, 7, 8, 9, 11 and
20 (293T Lysate, Santa Cruz Biotechnology, CA, USA) or 10 mg
of arazyme were separated in 10% SDS-PAGE and transferred to
a nitrocellulose membrane (Millipore, Billerica, MA). The
membranes were washed in Tris-buffered saline with Tween 20
(TBS-T, 10 mM Tris-HCl, pH 8, 150 mM NaCl and 0.05%
Tween 20) and blocked with 5% skimmed milk (Molico, Nestle,
Sa˜o Paulo, Brazil) in TBS-T for 16 hours at 4uC with shaking.
Membranes were then probed for 16 hours at 4uC with primary
antibodies specific for detection of arazyme (rabbit polyclonal
arazyme antibody produced as described above, diluted 1:200), or
anti-murine MMP-1, MMP-2, MMP-7, MMP-8, MMP-9, MMP-
11 or MMP-20 (Santa Cruz Biotechnology). After 1 hour
incubation with 1:1,000 rabbit peroxidase-conjugated secondary
antibody (Invitrogen), the immunoreactive proteins were detected
by enhanced chemiluminescence using ECL detection system (GE
Healthcare).
Immunoprecipitation
Total cell lysate of B16F10-Nex2 cells prepared by freeze/
thawing method as described above (500 mg of protein) was
incubated for 16 hours with 20 mg of rabbit antibody anti-arazyme
at 4uC with gentle shaking. Protein G-Sepharose (500 mL,
Amersham Biosciences) was added to the sample and incubated
at the same conditions. Beads were collected by centrifugation at
3,000 rpm for 5 min at 4uC and washed twice with PBS-0.05%
Tween 20 and once with PBS. Immunoprecipitated proteins were
dissolved by boiling in SDS gel loading buffer, separated from the
beads by centrifugation and subjected to Western blot as described
above.
In vitro cytotoxic effect mediated by arazyme-specific
purified IgG
B16F10-Nex2 cells (56103/100 mL) were cultivated in 96-wells
plate for 12 hours. Mouse arazyme-specific purified IgG or
irrelevant mouse IgG [21] were added at different concentrations,
with or without guinea-pig complement (1:80, Invitrogen). Viable
cells were counted after 24 hours in a hemocytometer in presence
of Trypan blue, and the frequency calculated compared to the
untreated control.
In vivo assays
C57Bl/6 mice were i.v. injected with 56105 B16F10-Nex2
melanoma cells, in the caudal vein. Starting on the 1st day after
tumor cell inoculation, active arazyme (3 mg/kg) or PBS was
administered i.p. every other day for 21 days. Pulmonary
metastatic nodules were counted using an inverted microscope
on the 22nd day.
For neutralization assay, B16F10-Nex2 melanoma cells (36106
cells/mL) were incubated in 1.5-mL microtubes for 1 hour at
37uC, 5% CO2 and gentle shaking, with PBS (control), 20 mg/mL
of active or ortho-phenantrolyne-inactivated arazyme (2 mM, 5
min). After three PBS washings, C57Bl/6 mice were injected i.v.
with 36105 tumor cells in serum-free RPMI, and pulmonary
metastatic nodules were counted 13 days after tumor cell
inoculation.
For treatment with arazyme-specific polyclonal antibodies, mice
were inoculated i.v. with 36105 B16F10-Nex2 cells and 24 hours
later, animals were treated i.p. with 0.3 mL antiserum from
arazyme-immunized rabbit, 0.3 mL of rabbit pre-immune serum,
or PBS. After 13 days the number of metastatic melanotic nodules
was counted.
Bacterial Arazyme Inhibits Metastatic Melanoma
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Statistical analysis
The data are represented as means 6 SE. Statistical analysis
was performed using Student’s t Test. Values (p) equal to or less
than 0.05 were considered significant. All experiments were
conducted two or more times. Reproducible results were obtained
and representative data are shown.
Results
Arazyme treatment significantly reduces lung melanoma
metastasis
C57Bl/6 mice were challenged intravenously with 56105
B16F10-Nex2 murine melanoma cells and treated intraperitone-
ally with 3 mg/kg of active arazyme for a period of 21 days on
alternate days. The control group received PBS. There was a
significant reduction in the number of metastatic pulmonary
nodules after 22 days in arazyme-treated compared to untreated
mice (Figure 1A and B). While five of seven animals in the control
group showed around 200 pulmonary nodules, all animals in the
treated group showed less than 20 nodules. This strong inhibition
of tumor metastasis was observed in all 3 independent experiments
performed.
Active, but not heat-inactivated arazyme, displays a
cytostatic effect on murine and human tumor cells in
vitro
After in vitro incubation of murine melanoma B16F10-Nex2 cells
with several doses of active arazyme, the supernatant was
discarded and only viable adherent cells were counted with
Trypan blue. It was observed that arazyme reduces the number of
viable adherent cells in a dose-dependent way. At a concentration
of 8 mg/mL, arazyme was able to detach all adherent cells after
24 hours (Figure 2A).
Arazyme was also able to reduce the number of viable adherent
cells after 48 hours incubation in human melanoma A2058 and
human uterine cervix carcinoma HeLa cells (Figure 2B).
B16F10-Nex2 cells treated with a high dose of active arazyme
(8 mg/mL) for 24 hours showed intense morphology alterations,
such as loss of substrate adhesiveness and cluster formation
(Figure 3A). This effect was dependent on the metalloprotease
Figure 1. Active arazyme reduces the number of pulmonary
metastatic nodules in the murine melanoma model. (A) C57Bl/6
mice were i.v. injected with 56105 B16F10-Nex2 melanoma cells.
Starting on the 1st day after tumor cell inoculation, active arazyme
(3 mg/kg) was administered i.p. every other day for 21 days. Melanotic
pulmonary nodules were counted using an inverted microscope on the
22nd day. Control group (n = 7), arazyme treated group (n = 5). The
average numbers of nodules and standard deviations are shown. (B)
Representative lung images of untreated and treated animals. One of
three independent experiments is represented. Scale bar, 5 mm. * p,
0.05.
doi:10.1371/journal.pone.0096141.g001
Figure 2. Active arazyme has a dose-dependent in vitro effect
on B16F10-Nex2 murine melanoma and human tumor cells. (A)
Murine melanoma B16F10-Nex2 cells were incubated with increasing
concentrations of arazyme for 24 and 48 hours. (B) A2058 and HeLa
tumor cells were treated with active arazyme for 48 hours. Cell viability
was measured as described in materials and methods.
doi:10.1371/journal.pone.0096141.g002
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activity of arazyme, since heat-inactivated protease neither
induced alterations on cell morphology (Figure 3A) nor interfered
with cell viability (Figure 3C).
Surprisingly, it was observed that most cells in the clusters
present in the culture supernatant after arazyme treatment were
viable, hence not stained by Trypan blue, and we next verified the
ability of these viable cells to proliferate after protease removal
from the culture medium. B16F10-Nex2 cells were treated with
several doses (0.5 to 10 mg/mL) of active arazyme for 72 hours,
and to avoid loss of enzyme activity by degradation in the culture
medium, arazyme was added at 0, 24 and 48 hours incubation
times. Plates were then centrifuged and the arazyme-containing
supernatant was carefully removed, leaving adherent and non-
adherent cells at the bottom of the well. Fresh culture medium
without arazyme was added, and cultures were further incubated
for additional 48 hours in the absence of the protease. After this
final incubation, the number of viable cells was slightly reduced in
arazyme-treated cultures compared to the untreated control, and
the number of non-viable cells was less than 10% in treated and
untreated cultures (Figure 3B).
To demonstrate that arazyme interferes with tumor cell
adhesion, murine B16F10-Nex2 and human A2058 melanoma
cells were treated in vitro with arazyme for 1 hour, plated and
incubated for additional 3 hours. Non-adherent cells were then
removed, and attached cells were colorimetrically quantified.
Adhesions of B16F10-Nex2 and A2058 cells were significantly
reduced by 80% and more than 90%, respectively (Figure 3D).
These results suggest that active arazyme is not directly
cytotoxic in human and murine tumor cells, but instead, has a
cytostatic effect, interfering with tumor cell adhesion to ECM and
neighbouring cells.
Arazyme cleaves tumor cell surface CD44 and reduces in
vitro and in vivo cell invasion
Proteases have been shown to influence the expression of
adhesion molecules on tumor cell surface, and one of such
molecules, CD44, is highly expressed in tumor cells [22,23]. CD44
has a role in B16F10-Nex2 cells migration and invasion [11,24].
After 1 hour incubation with 5 mg/mL of active arazyme, a
significant reduction on surface CD44 was detected on B16F10-
Figure 3. Active but not heat-inactivated arazyme has a cytostatic effect on murine melanoma B16F10-Nex2 cells. (A) Representative
images of tumor cells treated for 24 hours with 8 mg/mL of active or heat-inactivated arazyme. Control, untreated cells. (B) B16F10-Nex2 cells were
cultured for 72 hours, and different concentrations of active arazyme (0.5, 1, 5 or 10 mg/mL) were added on 0, 24 and 48 hours time points. The
supernatant was carefully removed after plate centrifugation (10 min, 2,500 rpm) and fresh culture medium without arazyme was added. After
24 hours, cells were counted in presence of Trypan blue and the percentage of viable and non-viable cells was calculated compared to untreated
control. (C) Tumor cells were treated with increasing concentrations of heat-inactivated arazyme for 48 hours. Viable cells were counted in presence
of Trypan blue. (D) B16F10-Nex2 and A2058 cells (56104 cells/well) were treated with arazyme (10 mg/mL) for 1 hour, plated on 96-wells plate, and
after incubation for 3 hours, non-adherent cells were removed by a PBS rinse and adherent cells were stained. Data are representative of three
independent experiments. p values are shown in the figure.
doi:10.1371/journal.pone.0096141.g003
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Nex2 cells (Figure 4A). This effect was abolished when the catalytic
activity of arazyme was inhibited by ortho-phenantroline
(Figure 4A). Reduction of CD44 molecules on the cell surface
was also observed in human melanoma A2058 cell line after
arazyme treatment (Figure S1A). The reduction on the tumor cell
surface CD44 was due to the catalytic activity of the protease,
since CD44 gene expression was not affected by arazyme
treatment in both tumor cell lines (Figure S1B).
Arazyme treatment reduced the invasiveness of B16F10-Nex2
melanoma cells in vitro as well as in vivo. For in vitro testing,
Matrigel-coated transwell chambers and fetal calf serum as
haptotactic stimulus were used. Matrigel contains the extracellular
matrix of murine sarcoma cell line, and cell penetration using this
material simulates the in vivo tumor cell invasion of connective
tissue and basal membrane. A dose-dependent reduction in
B16F10-Nex2 cell invasion after incubation with 5 or 10 mg/mL
of arazyme was observed (Figure 4B).
Additionally, B16F10-Nex2 cells were incubated for 1 hour at
37uC with active arazyme in the presence or not of ortho-
phenantroline, washed with PBS for enzyme/inhibitor removal
and injected endovenously in C57Bl/6 animals. After 13 days, the
number of lung nodules was counted. Treatment of melanoma
cells with arazyme reduced significantly the number of lung
nodules formed in vivo, and this effect was reversed by the
metalloprotease-inhibitor (Figure 4C).
Arazyme induces monospecific polyclonal antibodies
that are cytotoxic to tumor cells in vitro, cross-react with
tumor MMP-8, and are protective after passive transfer in
vivo
Guimara˜es-Ferreira et al [11] demonstrated that murine
antibodies induced after treatment with fastuosain or bromelain,
plant-derived proteolytic products, cross-reacted in ELISA with
cathepsins B and L, and were lytic to B16F10-Nex2 cells in vitro,
reacting with surface and cytoplasmic components expressed by
these cells.
Anti-arazyme monospecific antibodies were raised in C57Bl/6
mice, analyzed in ELISA (Figure 5A) and the IgG fraction purified
in a protein G column. It proved to be highly cytotoxic in vitro in
B16F10-Nex2 melanoma cells, in a dose-dependent manner, even
in the absence of complement (Figure 5B).
Polyclonal antibodies were also obtained at high titers in rabbits
immunized s.c. with arazyme using alum as adjuvant (Figure S2A).
Purified rabbit IgG were also directly cytotoxic in B16F10-Nex2
cells, and the effect increased with complement (Figure S2B).
To identify the possible targets in murine melanoma cells for the
antibodies raised against arazyme, the protein structure of the
enzyme was compared to other metallopeptidases. Based on their
amino acid sequences four metallopeptidases families are recog-
nized: astacins, serralysins, adamalysins and matrixins, collectively
classified as members of the metzincin superfamily. Using BLAST
program (http://blast.ncbi.nlm.nih.gov/Blast.cgi), it was observed
that arazyme (accession number AAX21094.1) showed similarity
ranging from 37 to 46% with murine matrix metalloproteases
(MMP) 1, 7, 8, 11 and 20 (Table 1). Moreover, as a member of
serralysin family, arazyme contains an elongated zinc-binding
motif, HEXXHXXGXXH, and a methionine-turn [17,25].
Topologically, MMP-8 (neutrophil collagenase) has a structure
similar to serralysins [25,26] including arazyme. We therefore
explored whether the anti-arazyme antibodies would recognize
tumor-cell associated MMPs.
Reactivity of anti-arazyme antibodies and monoclonal antibod-
ies to MMPs 1, 7, 8, 11 and 20 to total B16F10-Nex2 cell lysate
was compared in Western-blot. Monoclonal antibodies against
MMP-2 and MMP-9 were also included in this experiment
because both have a role in melanoma development [27,28].
Figure 4. Metalloprotease activity of arazyme reduces CD44
expression on tumor cell surface, and reduces in vitro and in
vivo the invasion of B16F10-Nex2 melanoma cells. (A) B16F10-
Nex2 cells were treated for 1 hour with 5 mg/mL of arazyme with or
without ortho-phenantrolyne (2 mM) and were then incubated with
FITC-conjugated anti-murine CD44 antibody. The full peak (black)
represents CD44 expression in untreated tumor cells and the open area
shows CD44 expression after treatment. (B) B16F10-Nex2 cells were
previously incubated with arazyme (5 or 10 mg/mL for 1 hour) and the
ability of these cells to invade matrigel was measured as described in
materials and methods. Results of three independent experiments were
grouped. (C) B16F10-Nex2 melanoma cells were previously incubated
for 1 hour at 37uC with 20 mg/mL of active arazyme, 2 mM ortho-
phenantrolyne-inactivated arazyme or saline solution. C57Bl/6 mice (5
animals/group) were i.v. inoculated with 36105 treated tumor cells and
lung nodules were counted after 15 days.*, p#0.05.
doi:10.1371/journal.pone.0096141.g004
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Monoclonal antibodies to MMP-8 recognized a component of
75 kDa in the B16F10-Nex2 lysate, with the same molecular
weight of recombinant MMP-8 (Figure 5C). Further, the same
component of 75 kDa was recognized by anti-arazyme Abs in
murine B16F10-Nex2 tumor lysate (Figure 5C) and in human
melanoma A2058 and human breast carcinoma SKBR3 cell
lysates (Figure S3). Monoclonal anti-MMP-8 antibodies cross-
reacted with purified arazyme (Figure 5C).
Monoclonal antibodies against the other MMPs tested showed
no specific reactivity with components of B16F10-Nex2 lysate, but
recognized the respective recombinant proteases used as control
(data not shown).
Figure 5. Arazyme treatment induces protease-specific antibodies that cross-react with matrix metallopeptidase 8 (MMP-8) and are
cytotoxic to B16F10-Nex2 cells. (A) Serum (10021 to 80021 dilutions) from i.p arazyme-treated or untreated C57Bl/6 mice were analyzed by ELISA
for arazyme-specific antibodies as described in materials and methods. Animals are represented individually. (B) In vitro cytotoxicity of anti-arazyme
antibodies. Murine arazyme-specific protein G-purified IgG (1.25 to 10 mg/well) was incubated in the presence or absence of guinea-pig complement
for 12 hours, viable cells were counted in presence of Trypan blue and compared to the untreated control. Cp, Complement and iAb, irrelevant
antibody.*, p#0.05. (C) B16F10-Nex2 cell extract, purified arazyme or recombinant MMP-8 were electrophoretically separated, blotted onto
nitrocellulose membrane and revealed with rabbit anti-arazyme or monoclonal anti-MMP-8 antibodies. (D) B16F10-Nex2 cell extract was
immunoprecipitated with Ab anti-arazyme, and the complex was collected with Sepharose-Protein-G beads. Western blotting of the precipitated
sample was revealed with rabbit anti-arazyme or monoclonal anti-MMP-8 antibodies.
doi:10.1371/journal.pone.0096141.g005
Table 1. Similarity between murine (Mus musculus) matrix metalloproteases and arazyme.
Protein Acession number Maximum score Query coverage
MMP-1 NP_114396.3 46.2 37%
MMP-7 NP_034940.2 42.0 32%
MMP-20 NP_038931.1 42.0 33%
MMP-8 NP_032637.3 38.9 33%
MMP-11 NP_032632.1 37.4 46%
Maximum scores over 30% are showed.
doi:10.1371/journal.pone.0096141.t001
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The cross reactivity of anti-arazyme with murine MMP-8 was
confirmed by immunoprecipitation. B16F10-Nex2 lysate was
incubated with anti-arazyme Abs, the complex was precipitated
with Sepharose-Protein G beads, and the eluted 75 kDa compo-
nent reacted with rabbit anti-arazyme Abs as well as with anti-
MMP-8 antibodies (Figure 5D).
Finally, we evaluated the ability of these anti-arazyme
antibodies to inhibit melanoma metastasis in vivo. C57Bl/6 mice
were challenged i.v. with 36105 B16F10-Nex2 murine melanoma
cells and treated i.p. with 5 doses of 300 mL of PBS (control group),
rabbit pre-immune or rabbit anti-arazyme serum, in alternate
days. Thirteen days after tumor inoculation, the number of lung
metastatic nodules was counted (Figure 6). Mice treated with anti-
arazyme serum were significantly protected against melanoma
metastasis development with an average number of lung nodules
at least 4 times lower than that in untreated animals.
Discussion
Despite all the efforts for metastatic cancer control during the
last decades, this is still a very aggressive and deadly disease. Novel
synthetic chemotherapeutic agents currently used in the clinics do
not show the expected effectiveness, and there is increasing
evidence for the potential for nature-derived compounds on
cancer prevention and therapy. Many anticancer agents available
today are plant-derived natural products or their analogs, but still
new treatment alternatives are necessary to overcome the pitfalls
in cancer treatment [29,30].
Recently, bacterial-derived products have being considered
promising therapeutic strategies to modulate the immune response
in various human diseases, and several compounds with
immunostimulatory properties were already described. Examples
of these compounds are bacterial-produced Toll-like receptor
(TLR) ligands and uracil, able to activate the innate immune
response and to modulate intestinal immunity, respectively
[31,32].
Tumor-secreted proteases are in general associated with tumor
progression, an effect attributed to ECM degradation, thus
facilitating the process of tumor cell invasion and metastasis
[33,34]. On the other hand, some studies have shown that
proteases may exert tumor suppressor effects. Exogenously added
plant-derived fastuosain, bromelain or papain, and mammalian
trypsin or chymotrypsin, show antitumor properties in preclinical
cancer models [13]. Even some endogenous proteinases have
showed antitumor effects, as MMP-8, MMP-12, MMP-19, MMP-
26, caspase 3, caspase 5 and 6, prostasin, ADAMTS1, among
others [33–35]. The molecular mechanisms by which these
proteases play antitumor activities are not completely unraveled.
In the present work, we show that arazyme, a bacterial
metalloprotease with commercial value displays antimetastatic
property in the preclinical model of B16F10 melanoma. Intraper-
itoneal treatment with this metalloprotease significantly reduced
the number of pulmonary nodules following intravenous injection
of melanoma cells. Interestingly, arazyme did not inhibit
subcutaneous B16F10-Nex2 melanoma development, when used
in a therapeutic protocol administered i.p. (data not shown).
In vitro, arazyme showed a dose-dependent cytostatic effect in
B16F10-Nex2 cells, reducing cell adhesion by reducing CD44
molecules on tumor cell surface. This caused detachment of
adherent tumor cells, released from the matrix substrate to form
clusters of live cells in the culture supernatant. When the active
protease was removed from the culture, tumor cells adhered again
and proliferated. Reduction of CD44 molecules on cell surface
dependend on the proteolytic activity of arazyme, since the heat-
inactivated protease was unable to cause the same effect.
Moreover, CD44 mRNA expression was not altered by arazyme
treatment of cells. Reduction of CD44 on tumor cells rendered
inhibition of Matrigel invasion by these cells, and arazyme-treated
tumor cells showed reduced lung colonization after endovenous
inoculation. Inhibition of arazyme proteolytic activity by heating
or by ortho-phenantroline abolished these effects. The cytostatic
effect of arazyme, reduction of CD44 molecules although with
normal CD44 mRNA expression, and reduction on cell adhesion
in vitro was also seen on human tumor cells.
Proteolytic enzymes may act on adhesion molecules that play an
important role in tumor development and metastasis [36]. Because
of the intense crosstalk between the molecules that compose the
ECM and the effects on tumor regulation, different therapeutic
approaches have been used targeting members of the integrin
family, CD44 and MMPs [37–39].
CD44 is a glycoprotein receptor that binds to extracellular
hyaluronic acid (HA), important in cell-cell and cell-ECM
Figure 6. Passive transfer of rabbit anti-arazyme polyclonal antibodies inhibited murine melanoma metastasis. (A) C57Bl/6 mice were
i.v. injected with 36105 B16F10-Nex2 melanoma cells. Starting on the 1st day after tumor cell inoculation, 5 doses of 300 mL of rabbit pre-immune (PI
serum) or the same volume of rabbit arazyme-specific immune serum was administered i.p. every other day. Melanotic pulmonary nodules were
counted using an inverted microscope thirteen days after tumor cell inoculation. Untreated control group, n = 7 and pre-immune/immune serum
treated groups, n = 5.*, p#0.05. (B) Representative images of lungs from animals treated as described in (A). Scale bar, 5 mm.
doi:10.1371/journal.pone.0096141.g006
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adhesion [40,41]. Different tumor cells have high expression of
CD44, which plays a critical role in tumor progression, because
degradation of HA facilitate tumor cell invasion and the spread of
cancer [42,43]. The lower expression of CD44, by using blocking
antibodies, proteases or specific ligands, may regulate tumor
metastasis [40,44,45]. Seemingly, the reversible cytostatic effect of
arazyme on B16F10-Nex2 cells involves proteolysis of CD44 that
reduces the adhesion of tumor cells to the matrix substrate. Detached
cells form cell clusters in the culture supernatant. These tumor cells,
however, are resistant to anoikis and can survive for some time [46–
48]. After enzyme removal, CD44 de novo synthesis reconstitutes its
surface expression, and cell cycle resumes after tumor cell adhesion.
We have previously shown that fastuosain, a cysteine-protease
from Bromelia fastuosa protected mice against murine melanoma
B16F10-Nex2 subcutaneous development, mainly by reduction of
CD44 expression, which led to decreased tumor cell invasion [11].
It was also demonstrated that inoculation of bromelain and
fastuosain in mice induced the production of polyclonal enzyme-
specific immunoglobulins that cross-reacted with cathepsins B and
L of murine origin that are highly expressed in B16F10 cells [11].
These bromelain- and fastuosain-specific antibodies were cytotoxic
in vitro to B16F10-Nex2 cells, suggesting that in vivo, the protective
effect of these cysteine proteases against murine melanoma could
be partially due to the activity of these induced antibodies.
Presently, we show that in vitro monospecific polyclonal anti-
arazyme antibodies are cytotoxic to tumor cells in a complement-
independent manner. Most importantly, passive transfer of
purified IgG fraction was protective in vivo, reducing significantly
the number of lung metastatic nodules in B16F10-Nex2
challenged mice. Interestingly, the arazyme-specific immunoglob-
ulins cross-react with MMP-8 expressed in B16F10-Nex2 cells,
and may interfere with tumor cell development in vivo. Anti-
arazyme antibodies recognized components of same molecular
weight in human tumor cell lysates, suggesting that these
antibodies can be cytotoxic also to human tumors.
MMP-8, also known as collagenase-2 or neutrophil collagenase,
is a protease that is mainly produced by neutrophils, but is also
involved in several pathologies, including cancer [49,50]. The role
of this MMP is not completely established in tumor development.
While some studies show the relationship between MMP-8 and
tumor progression, there are others associating MMP-8 with
tumor suppression, especially in melanoma [51–53]. Experiments
using MMP-8 genetically deficient mice showed the increased
incidence of skin cancer, and overexpression of MMP-8 in
melanoma cells decreased tumor invasion and up regulated the
adhesion of tumor cells to ECM [50,54]. The protective role of
MMP-8 against melanoma development was reinforced in a study
showing that MMP-8 is frequently mutated in melanoma [55].
Therefore, the wild type-proteolytic active MMP-8 displays tumor
suppressive effects due to inhibition of tumor migration, invasion
and metastasis, whereas mutant MMP-8 is inactive, allowing
melanoma progression [45–56].
Recently, Kim and collaborators [57] showed that arazyme
inhibited the secretion of inflammatory mediators by human
immortalized keratinocytes (HaCaT) and monocytic (THP-1) or
eosinophilic (EoL-1) tumor cell lines in vitro. These cells were
stimulated, and treatment with arazyme reduced the expression of
IL-6, IL-8, MCP-1/CCL-2 and TARC/CCL-17, suggesting that
arazyme may also have an immunomodulatory effect in vivo, that
should be investigated.
In summary, we describe here the strong antitumor effect of a
bacterial-derived natural product, the metalloprotease arazyme,
using the metastatic preclinical model of murine melanoma
B16F10-Nex2. The active protease reduced CD44 molecules at
tumor cell surface interfering with cell adhesion, causing a
cytostatic effect in vitro. Arazyme removal from culture allowed
tumor cells to adhere again and proliferate, since they were
resistant to anoikis. In addition, arazyme induced the production
of protease-specific IgGs that cross-reacted with tumor MMP-8.
These antibodies were cytotoxic in vitro to melanoma cells, and in
vivo reduced melanoma lung metastasis. We conclude that the
strong antitumor activity of arazyme against murine B16F10-Nex2
metastatic melanoma could be due to the direct activity of the
active protease on tumor cells in combination with the cytotoxic
arazyme-specific immunoglobulins cross-reactive with MMP-8
expressed by tumor cells, making this bacterial metalloprotease a
promising candidate for metastatic disease control.
Supporting Information
Figure S1 Metalloprotease activity of arazyme reduces
CD44 molecules on human melanoma cell surface, but
not interferes with CD44 gene expression. (A) A2058 cells
were treated for 1 hour with 20 mg/mL of arazyme in presence or
not of the inhibitor ortho-phenantroline, washed and incubated
with FITC-conjugated anti-human CD44 antibody. Open peaks
represent CD44 expression on untreated tumor cells and solid
curves show CD44 expression after arazyme treatment. (B) RT-
PCR showing CD44 relative gene expression on A2058 and
B16F10 cells treated for 1 hour with arazyme (10 mg/mL).
GAPDH and HPRT were used as the constitutive expression
control respectively for A2058 and B16F10-Nex2 cells.
(TIF)
Figure S2 Arazyme treatment induces rabbit protease-
specific antibodies that reduce B16F10-Nex2 cells via-
bility. (A) Serum (20021 to 25600021 dilutions) from arazyme-
immunized rabbits was analyzed by ELISA as described in
materials and methods. (B) In vitro cytotoxicity of murine anti-
arazyme antibodies: Rabbit policlonal arazyme-specific protein G-
purified IgG (2.5–20 mg/well) was incubated in the presence or
absence of guinea-pig complement for 12 hours, viable cells were
counted in presence of Trypan blue and percentage was calculated
compared to untreated control. Cp, Complement.*, p#0.05,
compared to Control.
(TIF)
Figure S3 Arazyme-specific antibodies recognize a
75 kDa component in B16F10-Nex2 and human tumor
cells lysate. B16F10-Nex2, SKBR3 and A2058 cell extract
(40 mg), were electrophoretically separated, blotted onto nitrocel-
lulose membrane and revealed with rabbit anti-arazyme antibod-
ies (1:200).
(TIF)
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